HealthyFisetin LOWNCT07195318
Fisetin Supplementation for Healthy Aging
A study testing Fisetin in people with Healthy, run by Ove Andersen at 1 site in Denmark.
Trial summary
There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Fisetin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteDenmark
- Study dates
- 24 Sep 2025to 31 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Middle-aged or older adult (≥50 years),
- Able to cooperate cognitively,
- Able to read and understand Danish,
Who cannot join
- Inability or unwillingness to take oral supplements,
- Chronic or recent (within 30 days) use of other anti-aging supplements,
- Chronic or recent (within 30 days) treatment with medications having anti-aging effects (e.g., metformin, rapamycin, semaglutide),
- Chronic or recent (within 30 days) treatment with anti-inflammatory medications,
- Chronic or recent (within 30 days) treatment with the medications that can interact negatively with fisetin,
- Recent (within 14 days) vaccination,
Show all 12Show fewer
- Treatment with another investigational drug or other intervention within 1 year,
- Active cancer or current cancer treatment,
- Unstable or uncontrolled major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer, requiring regular monitoring at the hospital
- Planned medical and surgical procedures during the study period,
- Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules,
- Presence of any condition that the investigator believes would put the participant at risk or would preclude the participant from successfully completing all aspects of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre
Hvidovre, 2650
Juliette Tavenier, +4538620958, juliette.tavenier@regionh.dk
About this study
Official title: Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial
There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.
The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.
Read the detailed description
The goal of this study is to assess the anti-inflammatory effects, overall health benefits, and the safety of a daily low dose (100 mg) of fisetin in relatively healthy middle-aged and older adults.
The study is a 2-arm triple-blind randomized placebo-controlled trial, in which middle-aged and older adults (n=120) will receive either:
- One capsule (100 mg) fisetin daily for 7 weeks (intervention group), or
- One capsule placebo daily for 7 weeks (control group).
- Conditions
- Healthy
- Being tested
- Fisetin, Placebo
- Keywords
- Chronic inflammation, Cellular senescence, Senotherapeutics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FisetinDietary supplement
One capsule (100 mg) daily
PlaceboDietary supplement
One capsule daily
| Study group | Role | What they receive |
|---|---|---|
| Treatment group | Experimental | Fisetin daily for 7 weeks Receives: Dietary Supplement: Fisetin |
| Placebo group | Placebo comparator | Placebo daily for 7 weeks Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Soluble urokinase plasminogen activator receptor (suPAR)
The difference between groups in the change in plasma levels of suPAR
Measured: Baseline to Week 7
Secondary outcomes (1)
Side effects
Differences between groups in the type and frequency of side effects
Measured: Baseline to Week 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start24 Sep 2025
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is a 2-arm triple-blind randomized placebo-controlled trial, in which middle-aged and older adults will receive either: * 100 mg fisetin daily for 7 weeks (intervention group), or * placebo daily for 7 weeks (control group).
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ove Andersen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ove Andersen, Hvidovre University Hospital
- Investigators
- Juliette Tavenier, Study chair, Copenhagen University Hospital, Amager and HvidovreLine Jee Hartmann Rasmussen, Study chair, Copenhagen University Hospital, Amager and HvidovreMorten B Houlind, Study chair, Copenhagen University Hospital, Amager and HvidovreMagnus Berglind, Study chair, Copenhagen University Hospital, Amager and HvidovreLine Fleischer Hach, Study chair, Copenhagen University Hospital, Amager and Hvidovre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07195318
- Sponsor's protocol ID
- H-25043857
- Acronym
- Fisetin LOW
- Status last verified
- May 2026
- First submitted
- 12 Sep 2025
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT07195318
- Acronym / sponsor ID
- Fisetin LOW / H-25043857
- Conditions
- Healthy
- Keywords
- Chronic inflammation, Cellular senescence, Senotherapeutics
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ove AndersenUniversity, hospital or other
- Study start
- 24 Sep 2025 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Oct 2026 (estimated)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.
The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.
Detailed description
The goal of this study is to assess the anti-inflammatory effects, overall health benefits, and the safety of a daily low dose (100 mg) of fisetin in relatively healthy middle-aged and older adults.
The study is a 2-arm triple-blind randomized placebo-controlled trial, in which middle-aged and older adults (n=120) will receive either:
- One capsule (100 mg) fisetin daily for 7 weeks (intervention group), or
- One capsule placebo daily for 7 weeks (control group).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- The study is a 2-arm triple-blind randomized placebo-controlled trial, in which middle-aged and older adults will receive either: * 100 mg fisetin daily for 7 weeks (intervention group), or * placebo daily for 7 weeks (control group).
| Arm | Type | Receives |
|---|---|---|
| Treatment group | Experimental | Dietary Supplement: FisetinFisetin daily for 7 weeks |
| Placebo group | Placebo comparator | Dietary Supplement: PlaceboPlacebo daily for 7 weeks |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Middle-aged or older adult (≥50 years),
- Able to cooperate cognitively,
- Able to read and understand Danish,
Key exclusion criteria (12 listed)
- Inability or unwillingness to take oral supplements,
- Chronic or recent (within 30 days) use of other anti-aging supplements,
- Chronic or recent (within 30 days) treatment with medications having anti-aging effects (e.g., metformin, rapamycin, semaglutide),
- Chronic or recent (within 30 days) treatment with anti-inflammatory medications,
- Chronic or recent (within 30 days) treatment with the medications that can interact negatively with fisetin,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FisetinOne capsule (100 mg) daily | Dietary supplement | Treatment group |
| PlaceboOne capsule daily | Dietary supplement | Placebo group |
Primary outcome
Soluble urokinase plasminogen activator receptor (suPAR)
Time frame: Baseline to Week 7
The difference between groups in the change in plasma levels of suPAR
1 secondary outcome
Side effects
Time frame: Baseline to Week 7
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Juliette Tavenier study chair
Copenhagen University Hospital, Amager and Hvidovre
Line Jee Hartmann Rasmussen study chair
Copenhagen University Hospital, Amager and Hvidovre
Morten B Houlind study chair
Copenhagen University Hospital, Amager and Hvidovre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fisetin in people with Healthy, run by Ove Andersen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Juliette Tavenier (+45 38620958, juliette.tavenier@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Soluble urokinase plasminogen activator receptor (suPAR) (time frame: Baseline to Week 7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.